• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
  • Nowy
Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

9780443345470
514,03 zł
436,93 zł Zniżka 77,10 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 436,93 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DHL, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jennifer R. Brown and Matthew S. Davids bring their considerable expertise to the topic of Chronic Lymphocytic Leukemia. Top experts provide in-depth perspectives on CLL, including basic biology, frontline and relapsed refractory treatments, mechanisms of resistance to targeted therapies, Richter’s transformation, and some of the common complications of the disease stemming from immune dysfunction-offering a state-of-the-art overview of the field to help optimize the care of patients with CLL.
Szczegóły produktu
Elsevier
103697
9780443345470
9780443345470

Opis

Rok wydania
2025
Numer wydania
1
Oprawa
twarda
Liczba stron
240
Wymiary (mm)
152 x 229
Waga (g)
450
  • Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia
    The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework for Understanding Biological and Clinical Heterogeneity
    Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton’s Tyrosine Kinase Inhibitors: A Comprehensive Overview
    First-line Therapy: Time-Limited Venetoclax Doublet Therapy
    Triplet Therapies in Chronic Lymphocytic Leukemia
    Measurable/Minimal Residual Disease: What Method and What Cut-Off?
    Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia
    Resistance to Bruton Tyrosine Kinase Inhibitors
    Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia
    Immunotherapy in Chronic Lymphocytic Leukemia
    Advances in the Understanding of Richter Transformation
    Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
    Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia
Komentarze (0)